- Home
- DALN vs AKTX Comparison
DALN vs AKTX Comparison
Compare DALN & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DALN
- AKTX
- Stock Information
- Founded
- DALN 1954
- AKTX N/A
- Country
- DALN United States
- AKTX United States
- Employees
- DALN N/A
- AKTX N/A
- Industry
- DALN Newspapers/Magazines
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- DALN Consumer Discretionary
- AKTX Health Care
- Exchange
- DALN Nasdaq
- AKTX Nasdaq
- Market Cap
- DALN 38.1M
- AKTX 41.8M
- IPO Year
- DALN 2008
- AKTX N/A
- Fundamental
- Price
- DALN $4.37
- AKTX $1.12
- Analyst Decision
- DALN
- AKTX
- Analyst Count
- DALN 0
- AKTX 0
- Target Price
- DALN N/A
- AKTX N/A
- AVG Volume (30 Days)
- DALN 15.3K
- AKTX 25.4K
- Earning Date
- DALN 07-29-2025
- AKTX 08-18-2025
- Dividend Yield
- DALN N/A
- AKTX N/A
- EPS Growth
- DALN N/A
- AKTX N/A
- EPS
- DALN 5.55
- AKTX N/A
- Revenue
- DALN $123,414,000.00
- AKTX N/A
- Revenue This Year
- DALN N/A
- AKTX N/A
- Revenue Next Year
- DALN N/A
- AKTX N/A
- P/E Ratio
- DALN $0.75
- AKTX N/A
- Revenue Growth
- DALN N/A
- AKTX N/A
- 52 Week Low
- DALN $2.98
- AKTX $0.85
- 52 Week High
- DALN $7.86
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- DALN 39.58
- AKTX 47.22
- Support Level
- DALN $3.82
- AKTX $1.08
- Resistance Level
- DALN $4.45
- AKTX $1.25
- Average True Range (ATR)
- DALN 0.24
- AKTX 0.08
- MACD
- DALN 0.00
- AKTX -0.01
- Stochastic Oscillator
- DALN 37.80
- AKTX 39.71
About DALN DallasNews Corporation Series A
DallasNews Corp is a local news and information publishing company in Texas with commercial printing, distribution, and direct mail capabilities, as well as a presence in emerging media and digital marketing.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.